You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lymphoma, Large-Cell

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral Trial (SGN-35T)

Not yet recruiting
  • Lymphoma, T-Cell, Cutaneous
  • +5 more
  • (no location specified)
Nov 2, 2023

Circular RNAs in ALKpositive Anaplastic Large-cell Lymphoma

Active, not recruiting
  • ALK-Positive Anaplastic Large Cell Lymphoma
  • RNAseq
  • Toulouse, France
    IUCT-Oncopole University Hospital
Jul 3, 2023

Mycosis Fungoides of Skin (Diagnosis), Cutaneous T-cell Lymphoma, Non Hodgkin Lymphoma Trial in Cleveland (Med-Jet Injector,

Not yet recruiting
  • Mycosis Fungoides of Skin (Diagnosis)
  • +5 more
  • Med-Jet Injector
  • +4 more
  • Cleveland, Ohio
    University Hospitals Cleveland Medical Center, Case Comprehensiv
Jan 17, 2023

DLBCL (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)

Active, not recruiting
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)

Recruiting
  • Diffuse Large Cell Lymphoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

High-Dose Methotrexate Clearance in Diffuse Large B-Cell

Recruiting
  • Central Nervous System Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Non-Interventional Study
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Sep 8, 2023

Recurrent DLBCL, Refractory Diffuse Large B-cell Lymphoma Trial in Tianjin (RC19D2 cell injection)

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-cell Lymphoma
  • RC19D2 cell injection
  • Tianjin, Tianjin, China
    Hematology Hospital of the Chinese Academy of Medical Sciences
Sep 14, 2023

Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory Trial in Hangzhou (Anlotinib HCl, Rituximab,

Recruiting
  • Diffuse Large B-cell Lymphoma Recurrent
  • Diffuse Large B Cell Lymphoma Refractory
  • Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Oct 12, 2023

Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
  • (no location specified)
Sep 5, 2023

Communication Training Intervention for Large B-Cell Lymphoma

Recruiting
  • Lymphoma, B-Cell
  • +5 more
  • Hematolo-GIST Training
  • Participants Appointment
  • New York, New York
  • +2 more
Jul 3, 2023

Relapsed or Refractory Diffuse Large B-cell Lymphoma Trial in Beijing (BEBT-908 for injection)

Active, not recruiting
  • Relapsed or Refractory Diffuse Large B-cell Lymphoma
  • BEBT-908 for injection
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Oct 8, 2023

Anaplastic Large Cell Lymphoma, Vinorelbine Trial in Shanghai (Vinorelbine)

Completed
  • Anaplastic Large Cell Lymphoma
  • Vinorelbine
  • Shanghai, Shanghai, China
    Shanghai Children's Medical Center
Jul 23, 2022

DLBCL Trial (Polatuzumab Vedotin)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • Polatuzumab Vedotin
  • (no location specified)
Jul 12, 2023

Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell

Active, not recruiting
  • Recurrent Anaplastic Large Cell Lymphoma
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 30, 2023

Large B-cell Lymphoma Trial (Glofitamab, Polatuzumab vedotin, Obinutuzumab)

Not yet recruiting
  • Large B-cell Lymphoma
  • (no location specified)
Oct 3, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab vedotin and Rituximab)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib, Polatuzumab vedotin and Rituximab
  • Shanghai, Shanghai, China
    Zhongshan Hospital，Fudan University
Jul 10, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab Vedotin, Rituximab)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib, Polatuzumab Vedotin, Rituximab
  • Shanghai, Shanghai, China
    Zhongshan Hospital，Fudan University
Jul 10, 2023

Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Diffuse Large B Cell Lymphoma
  • CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital
Nov 19, 2023

Diffuse Large B Cell Lymphoma Trial in Rouen (Measure of the circulating tumor DNA)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • Measure of the circulating tumor DNA
  • Rouen, France
    Centre Henri Becquerel
Nov 17, 2023

DLBCL Trial in Jinan (Mitoxantrone Hydrochloride Liposome Injection)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • Mitoxantrone Hydrochloride Liposome Injection
  • Jinan, Shandong, China
    Affiliated Cancer Hospital of Shandong First Medical University
May 16, 2023

Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb Trial in Guangzhou (Toripalimab,

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +5 more
  • Toripalimab, Rituximab
  • R-CHOP Protocol
  • Guangzhou, Guangdong, China
    Department of hematology department, Nanfang hospital
Apr 6, 2022

DLBCL Trial (Acalabrutinib, Rituximab)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • (no location specified)
Jul 11, 2023

Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Cyclophosphamide)

Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • (no location specified)
Mar 9, 2023

Aggressive Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma Trial in United States

Active, not recruiting
  • Aggressive Non-Hodgkin Lymphoma
  • +14 more
  • Cholecalciferol
  • Laboratory Biomarker Analysis
  • Scottsdale, Arizona
  • +4 more
Jan 16, 2023

DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial in Xiamen (Lenalidomide combined with G-CHOP (LO CHOP))

Recruiting
  • DLBCL - Diffuse Large B Cell Lymphoma
  • Follicular Lymphoma
  • Lenalidomide combined with G-CHOP (LO CHOP)
  • Xiamen, Fujian, China
    Bing Xu
Nov 28, 2023